全文获取类型
收费全文 | 8444篇 |
免费 | 645篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 245篇 |
妇产科学 | 238篇 |
基础医学 | 1446篇 |
口腔科学 | 194篇 |
临床医学 | 996篇 |
内科学 | 1668篇 |
皮肤病学 | 179篇 |
神经病学 | 861篇 |
特种医学 | 406篇 |
外科学 | 1034篇 |
综合类 | 72篇 |
一般理论 | 3篇 |
预防医学 | 676篇 |
眼科学 | 90篇 |
药学 | 467篇 |
中国医学 | 9篇 |
肿瘤学 | 466篇 |
出版年
2023年 | 43篇 |
2022年 | 56篇 |
2021年 | 129篇 |
2020年 | 95篇 |
2019年 | 163篇 |
2018年 | 171篇 |
2017年 | 139篇 |
2016年 | 186篇 |
2015年 | 169篇 |
2014年 | 218篇 |
2013年 | 347篇 |
2012年 | 442篇 |
2011年 | 418篇 |
2010年 | 241篇 |
2009年 | 228篇 |
2008年 | 363篇 |
2007年 | 419篇 |
2006年 | 421篇 |
2005年 | 391篇 |
2004年 | 346篇 |
2003年 | 341篇 |
2002年 | 345篇 |
2001年 | 281篇 |
2000年 | 286篇 |
1999年 | 273篇 |
1998年 | 132篇 |
1997年 | 94篇 |
1996年 | 97篇 |
1995年 | 71篇 |
1994年 | 78篇 |
1993年 | 71篇 |
1992年 | 185篇 |
1991年 | 155篇 |
1990年 | 138篇 |
1989年 | 168篇 |
1988年 | 127篇 |
1987年 | 127篇 |
1986年 | 110篇 |
1985年 | 109篇 |
1984年 | 98篇 |
1983年 | 74篇 |
1982年 | 46篇 |
1981年 | 42篇 |
1979年 | 69篇 |
1978年 | 36篇 |
1977年 | 50篇 |
1975年 | 33篇 |
1974年 | 44篇 |
1973年 | 37篇 |
1971年 | 37篇 |
排序方式: 共有9105条查询结果,搜索用时 21 毫秒
991.
Caroline Kampmeyer Sofie V. Nielsen Lene Clausen Amelie Stein Anne‐Marie Gerdes Kresten Lindorff‐Larsen Rasmus Hartmann‐Petersen 《Genes, chromosomes & cancer》2017,56(12):823-831
Inhibitors of molecular chaperones and the ubiquitin‐proteasome system have already been clinically implemented to counter certain cancers, including multiple myeloma and mantle cell lymphoma. The efficacy of this treatment relies on genomic alterations in cancer cells causing a proteostatic imbalance, which makes them more dependent on protein quality control (PQC) mechanisms than normal cells. Accordingly, blocking PQC, e.g. by proteasome inhibitors, may cause a lethal proteotoxic crisis in cancer cells, while leaving normal cells unaffected. Evidence, however, suggests that the PQC system operates by following a better‐safe‐than‐sorry principle and is thus prone to target proteins that are only slightly structurally perturbed, but still functional. Accordingly, implementing PQC inhibitors may also, through an entirely different mechanism, hold potential for other cancers. Several inherited cancer susceptibility syndromes, such as Lynch syndrome and von Hippel‐Lindau disease, are caused by missense mutations in tumor suppressor genes, and in some cases, the resulting amino acid substitutions in the encoded proteins cause the cellular PQC system to target them for degradation, although they may still retain function. As a consequence of this over‐meticulous PQC mechanism, the cell may end up with an insufficient amount of the abnormal, but functional, protein, which in turn leads to a loss‐of‐function phenotype and manifestation of the disease. Increasing the amounts of such proteins by stabilizing with chemical chaperones, or by targeting molecular chaperones or the ubiquitin‐proteasome system, may thus avert or delay the disease onset. Here, we review the potential of targeting the PQC system in hereditary cancer susceptibility syndromes. 相似文献
992.
993.
994.
HOPX is methylated and exerts tumour‐suppressive function through Ras‐induced senescence in human lung cancer 下载免费PDF全文
Yuan Chen Linlin Yang Tiantian Cui Manuela Pacyna‐Gengelbach Iver Petersen 《The Journal of pathology》2015,235(3):397-407
HOPX acts as a tumour suppressor in various cancers. However, the regulation of HOPX in human lung cancer as well as the mechanism underlying its tumour‐suppressive function has not yet been well elucidated. Here we investigated the epigenetic regulation and molecular mechanism by which HOPX exerts growth inhibitory effects. We found that HOPX was down‐regulated in 12 out of 13 lung cancer cell lines and in 69 out of 120 primary lung tumours at mRNA and protein levels. Patients with lung adenocarcinoma (ADC) exhibited significantly more positive staining of HOPX protein compared with lung squamous cell carcinoma (SCC) (p =0.036). Again in ADC, patients with higher HOPX expression had a significantly longer disease‐free survival (p =0.001). Methylation analysis showed that down‐regulation of HOPX was associated with DNA methylation (p =0.011). To analyse the function of HOPX in lung cancer cells, stable transfection with an expression vector of HOPX was performed. It turned out that HOPX inhibited tumour cell proliferation rate, migration, and invasion, and, more interestingly, forced expression of HOPX enhanced cellular senescence via activation of oncogenic Ras and the downstream MAPK pathway, which in turn led to decreased MDM2 and increased p21. On the contrary, knockdown of HOPX by siRNA resulted in reduced Ras activity, inactivation of the MAPK pathway, and decreased p21 levels, accompanied by reduced cellular senescence. Additionally, the HOPX‐induced senescence pathway was also active in human bronchial epithelial cells. Taken together, our data suggest that down‐regulation of HOPX was related to DNA methylation and that HOPX exerts tumour‐suppressive activity by oncogenic Ras‐induced cellular senescence in lung cancer cells. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
995.
The role of positron emission tomography-computed tomography (PET-CT) in surveillance of patients with nonsmall cell lung cancer (NSCLC) treated with curatively intended chemoradiotherapy remains controversial. However, conventional chest X-ray and computed tomography (CT) are of limited value in discriminating postradiotherapy changes from tumor relapse. The aim of this study was to evaluate the clinical value of PET-CT scan in the follow-up for patients with locally advanced (LA) NSCLC receiving concomitant chemoradiotherapy (CCRT).Between 2009 and 2013, eligible patients with stages IIB–IIIB NSCLC were enrolled in the clinical trial NARLAL and treated in Odense University Hospital (OUH). All patients had a PET-CT scan scheduled 9 months (PET-CT9) after the start of the radiation treatment in addition to standard follow-up (group A). Patients who presented with same clinical stage of NSCLC and received similar treatment, but outside protocol in OUH during this period were selected as control group (group B). Patients in group B were followed in a conventional way without PET-CT9. All patients were treated with induction chemotherapy followed by CCRT.Group A included 37 and group B 55 patients. The median follow-up was 16 months. Sixty-six (72%) patients were diagnosed with progression after treatment. At the time of tumor progression, patients in group A had better performance status (PS) than those in group B (P = 0.02). Because of death (2 patients), poor PS (3) or retreatment of relapse (9), only 23 patients had PET-CT9 in group A. Eleven (48%) patients were firstly diagnosed with progression by PET-CT9 without any clinical symptoms of progression. The median progression-free survival (PFS) was 8.8 months in group A and 12.5 months in group B (P = 0.04). Hazard function PFS showed that patients in group A had higher risk of relapse than in group B.Additional FDG PET-CT scan at 9 months in surveillance increases probability of early detection of disease progression in advanced NSCLC patients treated with curatively intended CCRT. 相似文献
996.
Kim Francis Andersen Hanna Maria Fuglo Sine Hvid Rasmussen Michael Mork Petersen Annika Loft 《Medicine》2015,94(28)
To assess the prognostic value of primary tumor metabolic activity in patients with high-grade bone sarcomas (BS) or soft tissue sarcomas (STS) using F-18 FDG PET/CT.A single-site, retrospective study including 92 patients with high-grade BS or STS. Pretreatment F-18 FDG PET/CT scan was performed. Clinical data were registered. Accuracy of maximum standardized uptake value of primary tumor (SUVmax) and tumor-to-background (T/B) uptake ratio as prognostic variables and identification of cut-off values to group patients were determined. Kaplan–Meier survival estimates and log-rank test were used to compare survival distributions. Prognostic variables were assessed using Cox proportional hazards regression analysis.Forty-one of 92 patients died during follow-up (45%). Average survival was 6.5 years (95% CI 5.8–7.3 years) and probability of 5-year survival was 52%. Accuracy of SUVmax and T/B uptake ratio as prognostic variables in all patients and during subgroup analysis of patients with STS was significant. No significant results for AUCs were registered in patients with BS. Surgery was independently prognostic for survival throughout multivariate regression analysis of all patients (P = 0.001, HR 3.84) and subgroup analysis (BS: P = 0.02, HR 11.62; STS: P = 0.005, HR 4.13). SUVmax was significant as prognostic variable in all patients (P = 0.02, HR 3.66) and in patients with STS (P = 0.007, HR 3.75). No significant results were demonstrated for T/B uptake ratio.Estimation of primary tumor metabolic activity with pretherapeutic SUVmax using F-18 FDG PET/CT demonstrates independent properties beyond histologic grading for prediction of survival in patients with high-grade STS, but not with high-grade BS. 相似文献
997.
Daniel F. Vatner Sachin K. Majumdar Naoki Kumashiro Max C. Petersen Yasmeen Rahimi Arijeet K. Gattu Mitchell Bears Jo?o-Paulo G. Camporez Gary W. Cline Michael J. Jurczak Varman T. Samuel Gerald I. Shulman 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(4):1143-1148
998.
B H Petersen 《Scandinavian journal of haematology》1977,18(3):235-243
Graded doses of syngeneic bone marrow cells were transplanted into lethally irradiated mice. Repopulation curves of peripheral blood granulocytes and platelets were apparently exponential and parallel after doses larger than 5 X 10(5) cells. The blood platelet Td was reduced from 111 h to 53-57 h, and granulocyte Td from 57 to 40 h in transplanted groups. The mean blood cell counts were reproducible enough to be used as a biological assay of the amount of bone marrow cells transplanted. Linear relationship between increment of blood cells up to day 16 and number of bone marrow cells transplanted on day 1 was demonstrated (1,200 granulocytes and 14,300 platelets/mul blood per 10(5) bone marrow cells). The linearity suggested a mean Td less than 22.5 h of proliferating bone marrow cells, and allowed a rough estimation of mouse bone marrow stem cell radiosensitivity (Do 76 rad). 相似文献
999.
S A J Schmidt G V S?rensen E Horváth-Puhó L Pedersen N Obel K L Petersen H C Sch?nheyder H T S?rensen 《British journal of cancer》2015,112(11):1822-1826
Background:
Herpes zoster (HZ) is associated with underlying immunodeficiency and may thereby predict mortality of subsequent cancer.Methods:
By using Danish nationwide medical databases, we identified all cancer patients with a prior hospital-based HZ diagnosis during 1982–2011 (n=2754) and a matched cancer cohort without prior HZ (n=26 243). We computed adjusted mortality rate ratios (aMRRs) associating prior HZ with mortality following cancer.Results:
Prior HZ was associated with decreased mortality within the year after cancer diagnosis (aMRR 0.87; 95% confidence interval (CI): 0.81–0.93), but not thereafter (aMRR 1.07; 95% CI: 0.99–1.15). However, prior HZ predicted increased mortality throughout the entire follow-up among patients aged <60 years (aMRR 1.39; 95% CI: 1.15–1.68) and those with disseminated HZ (aMRR 1.18; 95% CI: 1.01–1.37). The increased mortality rates were observed primarily for haematological and immune-related cancers.Conclusions:
Overall, HZ was not a predictor of increased mortality following subsequent cancer. 相似文献1000.
R Qin T C Smyrk N R Reed R L Schmidt T Schnelldorfer S T Chari G M Petersen A H Tang 《British journal of cancer》2015,112(3):514-522